ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck Achieves the Primary Objectives of Phase I of the EVICTION-2 Trial of ICT01 in Combination with Low Dose IL-2, Data Presented at AACR 2023
Science & Medicine 
Read more
ImCheck Appoints Thomas Civik as Independent Chairman of the Board
Leadership & Corporate 
Read more
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
Science & Medicine 
Read more

ASCO annual meeting

From  Jun 02, 2023  to  Jun 06, 2023 

Read more

Antibody engineering & Therapeutics Europe

From  Jun 06, 2023  to  Jun 08, 2023 

Read more

10th International Gamma-Delta T cell conference

From  Jun 20, 2023  to  Jun 23, 2023 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news